---
{"dg-publish":true,"permalink":"/research/takeaways/a-urolithin-a-dose-of-20-3-mg-kg-day-may-reduce-sinovitis/"}
---

# Assumptions
<div><ul class="dataview list-view-ul"></ul></div>

# Supporting Insights
<div><ul class="dataview list-view-ul"><li><span><a data-tooltip-position="top" aria-label="Research/Insights/A urolithin A dose of 250 mg-kg-day in a mouse equates to 20.3 mg-kg-day in a human.md" data-href="Research/Insights/A urolithin A dose of 250 mg-kg-day in a mouse equates to 20.3 mg-kg-day in a human.md" href="Research/Insights/A urolithin A dose of 250 mg-kg-day in a mouse equates to 20.3 mg-kg-day in a human.md" class="internal-link" target="_blank" rel="noopener" fileclass-name="Research Links">A urolithin A dose of 250 mg-kg-day in a mouse equates to 20.3 mg-kg-day in a human</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></li><li><span><a data-tooltip-position="top" aria-label="Research/Insights/Urolithin A may reduce knee sinovitis at a dose of 250 mg-kg-day, but not 50 mg-kg-day, compared to control when taken for 8 weeks after the induction of experimental arthritis at 4 months of age.md" data-href="Research/Insights/Urolithin A may reduce knee sinovitis at a dose of 250 mg-kg-day, but not 50 mg-kg-day, compared to control when taken for 8 weeks after the induction of experimental arthritis at 4 months of age.md" href="Research/Insights/Urolithin A may reduce knee sinovitis at a dose of 250 mg-kg-day, but not 50 mg-kg-day, compared to control when taken for 8 weeks after the induction of experimental arthritis at 4 months of age.md" class="internal-link" target="_blank" rel="noopener" fileclass-name="Research Links">Urolithin A may reduce knee sinovitis at a dose of 250 mg-kg-day, but not 50 mg-kg-day, compared to control when taken for 8 weeks after the induction of experimental arthritis at 4 months of age</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></li></ul></div>

# Original Sources
<div><table class="dataview table-view-table"><thead class="table-view-thead"><tr class="table-view-tr-header"><th class="table-view-th"><span>Source</span><span class="dataview small-text">2</span></th><th class="table-view-th"><span>Citation Key</span></th></tr></thead><tbody class="table-view-tbody"><tr><td><span>D’Amico, Davide, Merissa Olmer, Andréane M. Fouassier, Pamela Valdés, Pénélope A. Andreux, Chris Rinsch, and Martin Lotz. “Urolithin A Improves Mitochondrial Health, Reduces Cartilage Degeneration, and Alleviates Pain in Osteoarthritis.” Aging Cell 21, no. 8 (August 2022): e13662. <a rel="noopener" class="external-link" href="https://doi.org/10.1111/acel.13662" target="_blank">https://doi.org/10.1111/acel.13662</a>.</span></td><td><span><a data-tooltip-position="top" aria-label="Research/Evidence Sources/damicoUrolithinImprovesMitochondrial2022.md" data-href="Research/Evidence Sources/damicoUrolithinImprovesMitochondrial2022.md" href="Research/Evidence Sources/damicoUrolithinImprovesMitochondrial2022.md" class="internal-link" target="_blank" rel="noopener" fileclass-name="Research Links">damicoUrolithinImprovesMitochondrial2022</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td></tr><tr><td><span>USFDA. “Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers.” FDA, December 1, 2018. <a rel="noopener" class="external-link" href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/estimating-maximum-safe-starting-dose-initial-clinical-trials-therapeutics-adult-healthy-volunteers" target="_blank">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/estimating-maximum-safe-starting-dose-initial-clinical-trials-therapeutics-adult-healthy-volunteers</a>.</span></td><td><span><a data-tooltip-position="top" aria-label="Research/Evidence Sources/usfdaEstimatingMaximumSafe2018.md" data-href="Research/Evidence Sources/usfdaEstimatingMaximumSafe2018.md" href="Research/Evidence Sources/usfdaEstimatingMaximumSafe2018.md" class="internal-link" target="_blank" rel="noopener" fileclass-name="Research Links">usfdaEstimatingMaximumSafe2018</a><a class="metadata-menu fileclass-icon"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-package"><path d="m7.5 4.27 9 5.15"></path><path d="M21 8a2 2 0 0 0-1-1.73l-7-4a2 2 0 0 0-2 0l-7 4A2 2 0 0 0 3 8v8a2 2 0 0 0 1 1.73l7 4a2 2 0 0 0 2 0l7-4A2 2 0 0 0 21 16Z"></path><path d="m3.3 7 8.7 5 8.7-5"></path><path d="M12 22V12"></path></svg></a></span></td></tr></tbody></table></div>

# Database Fields